BioSpace News Archive

Nascum®-Plus works as a protective shield on the nasal mucosa where air pollutants trigger an allergic reaction

Riffyn has launched Riffyn Open Access which provides free use of its patented Scientific Development Environment (SDE) to any member of a non-profit organization.

Orchard Therapeutics today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to OTL-300, an investigational autologous ex vivo lentiviral gene therapy for the treatment of transfusion-dependent beta-thalassemia (TDBT), the most severe form of beta-thalassemia.

Dr. Oreola Donini, Senior Vice President and Chief Scientific Officer, discusses the Company’s ricin toxin vaccine with ROI-NJ.

Guardant Health went on the Nasdaq yesterday under the symbol GH. Shares climbed almost 70 percent on the first day of trading, selling 12.5 million shares at $19 per share in the initial public offering (IPO).

Despite an ongoing lawsuit over alleged theft of intellectual property, San Francisco-based Twist Bioscience plans to go public with an $86 million initial public offering.

Yesterday, Evotec AG (EVT) announced that Sanofi will be participating in an organized Public Private Partnership (PPP) that involves the initiation of brand newly formed BRIDGE, or LAB031, which was created to further the discovery of therapeutic drugs in multiple areas.

Transition continues as biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those transitions.

In lab studies, FL118 eliminated pancreatic tumors both alone and in combination with other drugs

e-therapeutics plc announces its interim results for the six months ended 31 July 2018.